[Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].

Authors:
  • HIHaruka Iwao
    Haruka Iwao
  • TSTomoyuki Sakai
    Tomoyuki Sakai
  • TSTomomi Sato
    Tomomi Sato
  • TNTakuji Nakamura
    Takuji Nakamura
  • ANAkio Nakajima
    Akio Nakajima
  • MMMiyuki Miki
    Miyuki Miki
  • TSToshioki Sawaki
    Toshioki Sawaki
  • MTMasao Tanaka
    Masao Tanaka
  • YMYasufumi Masaki
    Yasufumi Masaki

  • 1 May 2012
    • journal article
    • case report
Abstract
A 74-year-old female with relapsed multiple myeloma was treated with twice-weekly bortezomib plus dexamethasone (BD)therapy, but severe gastrointestinal adverse events(grade 3 paralytic ileus and constipation)developed. After changing to once-weekly BD therapy, ≥ grade 3 gastrointestinal adverse events did not develop, and she was able to continue BD therapy. A complete response and a treatment-free interval ≥ 2 years were obtained by 8 courses of BD therapy. This case report suggests that once-weekly BD therapy may reduce severe gastrointestinal adverse events without decreasing the clinical efficacy for multiple myeloma.